Shi K, Zhao Y, Miao L, Satterlee A, Haynes M, Luo C, Musetti S, Huang L. Dual functional LipoMET mediates envelope-type nanoparticles to combinational oncogene silencing and tumor growth inhibition. Mol Ther. 2017 Jul 5;25(7):1567-79. doi: 10.1016/j.ymthe.2017.02.008
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Renck-Hooper U, McKenna SP, Whalley D. Measuring quality of life in female urinary urge incontinence: development and psychometric properties of the IQoLI. J Drug Assess. 1998;1:41-8.